In May 2019, a trial at Nanjing University Medical center began comparing dapagliflozin to liraglutide, and also to the anti-diabetic medication acarbose, for their respective effects on cognitive and olfactory functionality in 87 overweight persons whose Kind 2 diabetes is inadequately managed with metformin alone. Constantly tell your health practitioner https://baltasarx110jwh4.wikipresses.com/user